PUBLISHER: The Business Research Company | PRODUCT CODE: 1946634
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946634
Gene therapy aims to correct faulty genes responsible for disease development, while nucleic acid-based therapeutics are employed to address genetic disorders and conditions without a definitive cure, such as anemia, sickle cell disease, cystic fibrosis, and thalassemia.
The key technologies include anti-sense and anti-gene strategies, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and other innovative approaches. Nucleoside analogues, a significant class of antiviral agents, are commonly utilized to combat conditions like human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV) infections. These therapeutic approaches find applications in various medical fields, including oncology, the management of conditions like muscular dystrophy and muscular disorders, and the treatment of rare diseases. They are implemented by end-users, including hospitals, clinics, academic institutions, and research centers, where cutting-edge research and development efforts are often carried out.
Tariffs are impacting the nucleic acid based gene therapy market by increasing costs of imported laboratory reagents, delivery vectors, bioprocessing equipment, nucleic acid synthesis tools, and advanced analytical instruments. Research institutes and biotech manufacturers in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces cost pressures on export-oriented biopharmaceutical production. These tariffs are increasing development costs and lengthening commercialization timelines. However, they are also driving domestic manufacturing of reagents, local bioprocess innovation, and regional capacity building in gene therapy production infrastructure.
The nucleic acid based gene therapy market research report is one of a series of new reports from The Business Research Company that provides nucleic acid based gene therapy market statistics, including nucleic acid based gene therapy industry global market size, regional shares, competitors with a nucleic acid based gene therapy market share, detailed nucleic acid based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid based gene therapy industry. This nucleic acid based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nucleic acid based gene therapy market size has grown rapidly in recent years. It will grow from $0.88 billion in 2025 to $0.97 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to advancements in molecular biology research, increased understanding of genetic disease mechanisms, expansion of clinical trials for gene therapies, rising investment in biotechnology research, early regulatory approvals for nucleic acid therapies.
The nucleic acid based gene therapy market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing adoption of crispr-based treatments, rising demand for rare disease therapies, expansion of gene therapy manufacturing facilities, growing focus on personalized oncology treatments, increasing public and private funding for genetic medicine. Major trends in the forecast period include increasing adoption of rna-based therapeutics, rising use of viral and non-viral gene delivery systems, growing focus on targeted gene editing technologies, expansion of personalized genetic therapies, enhanced emphasis on precision medicine applications.
The increasing financial support from governments and companies is anticipated to drive the growth of the nucleic acid-based gene therapy market in the coming years. Financial support includes investments, grants, and subsidies provided by public or private organizations to promote the research, development, and commercialization of therapies. The growth in financial support is attributed to the rising global focus on addressing rare and genetic diseases that currently have limited or no effective treatments. Government funding for nucleic acid-based gene therapy accelerates advancement by providing critical resources for research, clinical trials, and infrastructure, which directly foster innovation and the translation of therapies into clinical applications. For example, in July 2023, according to the U.S. National Institutes of Health, a U.S.-based federal health research agency, more than $140 million was allocated to accelerate genome-editing approaches, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders, representing a notable increase from the $92 million awarded in 2022. Therefore, the rising financial support from governments and companies is contributing to the expansion of the nucleic acid-based gene therapy market.
Major companies operating in the nucleic acid-based gene therapy market are prioritizing personalized, autologous stem cell therapies, such as genetically modified hematopoietic stem cell infusions, to address rare inherited disorders. Autologous therapies involve treatments in which a patient's own stem cells are harvested, genetically corrected, and then reintroduced to restore the missing biochemical function. For example, in March 2024, Orchard Therapeutics, a US-based pharmaceutical company, announced that Lenmeldy (atidarsagene autotemcel) received approval from the U.S. Food and Drug Administration for the treatment of children with metachromatic leukodystrophy (MLD). Lenmeldy utilizes the patient's own hematopoietic stem cells that are genetically modified to express a functional ARSA gene, thereby enabling enzyme restoration within the nervous system. This regulatory milestone highlights how companies are able to commercialize complex autologous gene therapies despite high manufacturing costs.
In March 2023, Moderna, Inc., a US-based biotechnology company, announced a partnership with Generation Bio. This collaboration aims to develop innovative nucleic acid therapeutics, including therapies designed to target immune cells, to advance both companies' pipelines of non-viral genetic medicines. Under the agreement, Moderna will fund all research and development activities related to this partnership, including a pre-payment to support research efforts. Generation Bio, also a US-based biotechnology company, specializes in nucleic acid-based gene therapies.
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the nucleic acid based gene therapy market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nucleic Acid Based Gene Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses nucleic acid based gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for nucleic acid based gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nucleic acid based gene therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.